1,721,076 research outputs found
Angiotensin-converting enzyme gene insertion/deletion polymorphism and susceptibility to psoriasis: a systematic review and meta-analysis
No full text
Interpretation and dynamics of the natural history of Mycobacterium ulcerans infection (Burli Ulcer)
No full textEndoplasmic reticulum aminopeptidase 1 (ERAP1) polymorphisms and psoriasis susceptibility: A systematic review and meta-analysis
No full textEvaluation of serum lipid, lipoprotein, and apolipoprotein levels in psoriatic patients: A systematic review and meta-analysis of case-control studies
No full text
Clinical implications of acquired braf inhibitors resistance in melanoma
Full text linkUnderstanding the role of mitogen-activated protein kinase (MAPK) pathway-activating mutations in the development and progression of melanoma and their possible use as therapeutic targets has substantially changed the management of this neoplasm, which, until a few years ago, was burdened by severe mortality. However, the presence of numerous intrinsic and extrinsic mechanisms of resistance to BRAF inhibitors compromises the treatment responses’ effectiveness and durability. The strategy of overcoming these resistances by combination therapy has proved successful, with the additional benefit of reducing side effects derived from paradoxical activation of the MAPK pathway. Furthermore, the use of other highly specific inhibitors, intermittent dosing schedules and the association of combination therapy with immune checkpoint inhibitors are promising new therapeutic strategies. However, numerous issues related to dose, tolerability and administration sequence still need to be clarified, as is to be expected from currently ongoing trials. In this review, we describe the clinical results of using BRAF inhibitors in advanced melanoma, with a keen interest in strategies aimed at overcoming resistance
Storia naturale della psoriasi: dalle forme cutanee parcellari all'eritrodermia e alle artropatie
No full textNicotinamide: a multifaceted molecule in skin health and beyond
Full text linkNicotinamide (NAM), the amide form of vitamin B3, is a precursor to essential
cofactors nicotinamide adenine dinucleotide (NAD+) and NADPH. NAD+ is integral to
numerous cellular processes, including metabolism regulation, ATP production, mitochondrial
respiration, reactive oxygen species (ROS) management, DNA repair, cellular
senescence, and aging. NAM supplementation has demonstrated efficacy in restoring
cellular energy, repairing DNA damage, and inhibiting inflammation by suppressing proinflammatory
cytokines release. Due to its natural presence in a variety of foods and its
excellent safety profile—even at high doses of up to 3 g/day—NAM is extensively used in
the chemoprevention of non-melanoma skin cancers and the treatment of dermatological
conditions such as blistering diseases, atopic dermatitis, rosacea, and acne vulgaris. Recently,
its anti-aging properties have elevated NAM’s prominence in skincare formulations.
Beyond DNA repair and energy replenishment, NAM significantly impacts oxidative stress
reduction, cell cycle regulation, and apoptosis modulation. Despite these multifaceted
benefits, the comprehensive molecular mechanisms underlying NAM’s actions remain not
fully elucidated. This review consolidates recent research to shed light on these mechanisms,
emphasizing the critical role of NAM in cellular health and its therapeutic potential.
By enhancing our understanding, this work underscores the importance of continued exploration
into NAM’s applications, aiming to inform future clinical practices and skincare
innovations
- …
